close

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company's other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	46.48
Volume	(mio) 1.08
Volume Avg	970302
52 Week High	53.10
52 Week Low	23.50
PE	17.94
PE (group average)	N/A
EPS Year	2.67
EPS change Q/Q	-12.9%
EPS change Q/Q Yr ago	980%
EPS change Q/Q next Q est	-50.46%
EPS change Y/Y	-81.06%
REV change Q/Q	-4.68%
REV change Q/Q Yr ago	44.6%
EPS next Q est	1.09
EPS next Y est	4.67
Divident Annual	0.00
Dividend Yield	0%